Breaking Down the Long-Term Results In a significant development for oncology, Moderna and Merck have released updated 5-year follow-up data from the Phase 2b KEYNOTE-942 clinical trial. This study investigates the combination of mRNA-4157 (V940), an investigational individualized neoantigen therapy, alongside Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, for patients with resected high-risk melanoma. What the Data…